The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells.
Adjuvants, Immunologic
/ administration & dosage
Animals
Antigens, CD
/ immunology
Cancer Vaccines
Dendritic Cells
/ immunology
Dinucleoside Phosphates
/ administration & dosage
Female
Immunoglobulin G
/ immunology
Injections, Subcutaneous
Lectins, C-Type
/ immunology
Mice
Mice, Inbred C57BL
Minor Histocompatibility Antigens
/ immunology
Oligodeoxyribonucleotides
/ administration & dosage
Ovalbumin
/ administration & dosage
Poly I-C
/ administration & dosage
Receptors, Cell Surface
/ immunology
Specific Pathogen-Free Organisms
Vaccination
Adjuvant
Cell mediated immunity
DC targeting
DEC-205
Poly(I:C)/CpG
Subcutaneous route
c-di-AMP
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
14 08 2019
14 08 2019
Historique:
received:
30
01
2019
revised:
30
05
2019
accepted:
06
07
2019
pubmed:
20
7
2019
medline:
7
10
2020
entrez:
20
7
2019
Statut:
ppublish
Résumé
Vaccination is the most efficient strategy to protect from infectious diseases and the induction of a protective immune response not only depends on the nature of the antigen, but is also influenced by the vaccination strategy and the co-administration of adjuvants. Therefore, the precise monitoring of adjuvant candidates and their immune modulatory properties is a crucial step in vaccine development. Here, one central aspect is the induction of appropriate humoral and cellular effector mechanisms. In our study we performed a direct comparison of two promising candidates in adjuvant development, the STING activator bis-(3,5)-cyclic dimeric adenosine monophosphate (c-di-AMP) and the Toll-like receptor ligand formulation poly(I:C)/CpG. These were evaluated in C57BL/6 mice using the model antigen ovalbumin (OVA) in subcutaneous vaccination with soluble protein as well as in a dendritic cell (DC) targeting approach (αDEC-OVA). Strikingly, c-di-AMP as compared to poly(I:C)/CpG resulted in significantly higher antigen-specific IgG antibody levels when used in immunization with soluble OVA as well as in antigen targeting to DC. In vaccination with soluble OVA, c-di-AMP induced a significantly stronger CTL, Th1 and IFNγ-producing CD8
Identifiants
pubmed: 31320219
pii: S0264-410X(19)30910-7
doi: 10.1016/j.vaccine.2019.07.019
pii:
doi:
Substances chimiques
Adjuvants, Immunologic
0
Antigens, CD
0
Cancer Vaccines
0
DEC-205 receptor
0
Dinucleoside Phosphates
0
Immunoglobulin G
0
Lectins, C-Type
0
Minor Histocompatibility Antigens
0
Oligodeoxyribonucleotides
0
Receptors, Cell Surface
0
cyclic diadenosine phosphate
0
Ovalbumin
9006-59-1
Poly I-C
O84C90HH2L
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4963-4974Informations de copyright
Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.